Annals of Oncology Advance Access first published online on January 12, 2006
This version published online on May 5, 2006
Annals of Oncology, doi:10.1093/annonc/mdj132
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Medizinische Klinik, Klinikum Augsburg, Germany
* To whom correspondence should be addressed. Morbidity and mortality in patients with malignancies are increased by viral infections. These mostly are reactivations of asymptomatic latent infections. They primarily concern clinical entities associated with the reactivation of herpes viruses, such as varicella zoster virus (VZV) and cytomegalovirus (CMV). Respiratory tract infections caused by influenza, parainfluenza or respiratory syncytial virus (RSV) are less common. Since reactivation of latent infections has major clinical impact, antiviral prophylaxis is an attractive approach for patients expecting immunosuppression. The main risk factor for clinically relevant reactivation is profound disruption of cellular immune response. Duration and severity of chemotherapy induced neutropenia are of lesser importance. The risk of viral complications rises significantly in the presence of sustained suppression of T-cell function, e.g. in recipients of allogeneic stem cell transplants or of alemtuzumab (Campath-1H) antibody therapy. The objective of this guideline is to review the basis of prophylactic strategies and to provide recommendations for clinicians treating patients with haematological malignancies and solid tumors. The original version was mistakenly published as an original article.
Received May 31, 2005
Revised December 4, 2005
Accepted December 5, 2005
review
Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO)
M. Sandherr 1 *,
H. Einsele 2,
H. Hebart 3,
C. Kahl 4,
W. Kern 5,
M. Kiehl 6,
G. Massenkeil 7,
O. Penack 8,
X. Schiel 9,
S. Schuettrumpf 10,
A. J. Ullmann 11,
and
O. A. Cornely 12
2 Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Germany
3 Klinikum Schwäbisch Gmünd, Zentrum für Innere Medizin, Germany
4 Abteilung Haematologie und Onkologie, Klinik und Poliklinik für Innere Medizin, Universität Rostock, Germany
5 Universitätsklinik Freiburg, Germany
6 Klinik für Innere Medizin, Klinikum Frankfurt (Oder), Germany
7 Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Charite - Campus Virchow Klinikum - Berlin, Germany
8 Medizinische Klinik III, Charite - Campus Benjamin-Franklin - Berlin, Germany
9 Medizinische Klinik und Poliklinik III, Klinikum der Universität München-Grosshadern, Germany
10 Zentrum Innere Medizin - Abteilung Hämatologie und Onkologie, Georg-August Universität Göttingen, Germany
11 Klinikum Johannes Gutenberg-Universität, III. Medizinische Klinik und Poliklinik, Mainz, Germany
12 Klinik I für Innere Medizin, Hämatologie - Onkologie - Infektiologie, Klinikum der Universität zu Köln, Germany
M. Sandherr, E-mail: michael.sandherr{at}lrz.tum.de
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. C. Wade Viral Infections in Patients with Hematological Malignancies Hematology, January 1, 2006; 2006(1): 368 - 374. [Abstract] [Full Text] [PDF]
|
|